Gd-EOB-DTPA-enhanced MR imaging findings of hepatocellular adenoma:Correlation with pathological findings

Magnetic Resonance in Medical Sciences

Volumn 10, Issue 4, 2011, Pages 245-249

  Takara, Kenichi ^a   Saito, Kazuhiro ^a   Kusama, Hiroshi ^a   Tsuchida, Akihiko ^a   Aoki, Tatsuya ^a   Nagao, Toshitaka ^a   Imai, Yasuharu ^a   Taira, Junichi ^a   Moriyasu, Fuminori ^a   Tokuuye, Koichi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; Gd EOB DTPA; Hepatocellular adenoma

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM ETHOXYBENZYL DTPA; GADOLINIUM PENTETATE;

ADULT; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LIVER ADENOMA; LIVER TUMOR; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ADENOMA, LIVER CELL; ADULT; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING;

EID: 84860238173     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.10.245     Document Type: Article

References (10)

1. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma:quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4:1-9.
2. Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann HP. MRI of hepatic adenomatosis: Initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol 2008; 190:W290-W293.
3. Jung G, Breuer J, Poll LW, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006; 47:15-23.
4. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopatho-logic findings and spiral CT-initial observations. Radiology 2005; 234:468-478.
5. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoen-berg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: Results of a multicenter trial. Invest Radiol 2008; 43:504-511.
6. Lewin M, Handra-Luca A, Arrivè L, et al. Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology 2006; 241:433-440.
7. Yamamoto A, Tamada T, Sone T, Higashi H, Yamashita T, Ito K. Gd-EOB-DTPA-enhanced magnetic resonance imaging findings of non diffuse fatty change of the liver. J Comput Assist Tomogr 2010; 34:868-873.
8. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183.
9. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 2010; 256:817-826.
10. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroen-terol 2009; 44:793-798.